IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This study is currently recruiting participants.
Verified June 2017 by National Cancer Institute (NCI)
Sponsor:
National Cancer Institute (NCI)
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT02446600
First received: May 11, 2015
Last updated: July 13, 2017
Last verified: June 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Study Completion Date: | No date given |
| Estimated Primary Completion Date: | December 31, 2019 (Final data collection date for primary outcome measure) |